Multidrug resistance (MDR) resulting in chemotherapy failure has become a major cancer treatment issue, and of the many reported mechanisms, ATP-binding cassette (ABC) transporters are predominantly responsible for MDR. 1 The overexpression of P-glycoprotein (P-gp), an ATP-binding cassette (ABC) transporter, has been demonstrated not only to be primarily involved in the incapacitation of a variety of widely used anticancer agents, such as, paclitaxel (Taxol), doxorubicin, and vinorelbine, but also is observed much more frequently than other ABC transporters. However, despite the developments of a number of P-gp inhibitors to overcome MDR, no drug is currently clinically available. A number of drug candidates have been dropped because of critical limitations, such as, intrinsic toxicity and pharmacokinetic interactions. Furthermore, few accurate methods are available for identifying patients that might benefit from MDR inhibition. However, advanced functional imaging technology using 99m Tc-sestamibi enables cancer patients responsive to P-glycoprotein modulation to be identified. 2 This advance and the hitherto unmet clinical need create a need for a large pool of novel drug candidates with high potency and selectivity. Herein, we report on a new class of highly potent MDR reversal compounds.
The aldol condensation of p-tolualdehyde with 2-butanone in the presence of 4 M HCl in 1,4-dioxane provided α,β-unsaturated ketone 2, which was readily converted into oxime 3 by hydroxylamine. Following treatment with MnO 2 afforded the desired isoxazole 4.
3 Mono-chlorosulphonylation 4 of isoxazole 4 gave the key intermediate 5, and the coupling of 5 with appropriate amine fragments provided the desired sulfonamide derivatives (Scheme 2).
The abilities of compounds to reverse MDR were examined using highly resistant human sarcoma MES-SA/DX5 cells, a P-gp overexpressing cancer cell line. The reversal activities of all synthesized compounds are summarized in table 1. The activities were evaluated with IC50 values of Taxol enhanced by co-treatment with 1 µM and 5 µM of each compound. The IC50 value of taxol against MES-SA/DX5 was 7.5 µM, although taxol usually has an IC50 value in the 1-10 nanomolar level against MES-SA, a non-MDR cancer cell line. Analogs bearing either the piperidino ethyl group (8) or the morpholino ethyl group (9), which lack aromatic rings, were inactive. On the other hand, most analogs with an aromatic group showed reversal activity. Benzyl piperazine 6 and fluorobenzyl piperazine 7 were too toxic at 5 µM, and inactive and moderately active at 1 µM, respectively. Compounds 10 and 12 were as active as verapamil, 5 a well-known P-gp inhibitor. In particular, 5 µM of compound 10 made MDR cancer cells 52-fold more sensitive to Taxol. Furthermore, fluorination (11) improved reversal activity, but also slightly increased intrinsic cytotoxicity. 1,2,3,4-tetrahydroisoquinolone, a cyclic form of phenethylamine was introduced to make the flexible phenethyl side chain more rigid. Compared to compound 10, rigidification of the phenethyl side chain (14) lowered intrinsic cytotoxicity and maintained reversal activity. Dimethoxy tetrahydroisoquinoline 15 at 5 µM was toxic, but at 1 µM displayed weak toxicity and good reversal activity. We next tried to introduce the common side chain of highly active P-gp inhibitors into this scaffold. Compound 17 completely reversed the potency of Taxol at 5 µM. The IC50 of Taxol against resistant cells was found to be < 10 nM in the presence of 5 µM of compound 17, which was almost the same as its IC50 against the sensitive cell line, MES-SA. To compare directly the isoxazoles with verapamil, we determined their EC50 values in the presence of 100 nM Taxol (Table 2) . 6 Compounds 10, 12, and 14 were found to have inhibitory effects that were slightly better than verapamil. Compound 15 was 3.2-fold better than verapamil, but had GI50 value of 12.1 µM. Compound 17 was 10-fold better than verapamil, and displayed acceptable cytotoxicity (GI50 = 17.4 µM versus EC50 = 0.68 µM).
In summary, we developed highly potent MDR reversing small molecules without intrinsic cytotoxicity. Compound 17 showed excellent reversal activity, which was about 10-fold better than verapamil. Further manipulation of these isoxazoles may lead to the developments of MDR modulators with clinical potential.
